Brooktree Capital Management Raises Position in Pfizer Inc. (NYSE:PFE)

Brooktree Capital Management raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 115,383 shares of the biopharmaceutical company’s stock after buying an additional 1,389 shares during the period. Pfizer comprises approximately 2.3% of Brooktree Capital Management’s portfolio, making the stock its 12th largest position. Brooktree Capital Management’s holdings in Pfizer were worth $3,061,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 11.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company’s stock valued at $3,766,366,000 after acquiring an additional 12,864,343 shares during the period. Nordea Investment Management AB lifted its position in Pfizer by 36.1% in the fourth quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company’s stock valued at $108,002,000 after purchasing an additional 1,080,822 shares during the last quarter. Parsons Capital Management Inc. RI boosted its stake in shares of Pfizer by 118.7% during the fourth quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company’s stock valued at $7,820,000 after purchasing an additional 159,984 shares during the period. Parnassus Investments LLC grew its holdings in shares of Pfizer by 3.7% in the third quarter. Parnassus Investments LLC now owns 4,390,705 shares of the biopharmaceutical company’s stock worth $127,067,000 after purchasing an additional 156,894 shares during the last quarter. Finally, TrinityPoint Wealth LLC increased its stake in shares of Pfizer by 85.5% in the third quarter. TrinityPoint Wealth LLC now owns 191,544 shares of the biopharmaceutical company’s stock worth $5,543,000 after buying an additional 88,258 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of PFE stock opened at $26.07 on Tuesday. The company’s fifty day moving average price is $26.22 and its 200-day moving average price is $27.10. The stock has a market cap of $147.72 billion, a PE ratio of 18.49, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PFE has been the subject of several analyst reports. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Wednesday, March 12th. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.